New Drug Approvals

Empagliflozin and Metformin Hydrochloride Tablets 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5mg/1000 mg Approved: July 7, 2022 - Zydus Pharmaceuticals (USA) Inc. Treatment for: Type 2 Diabetes Generic for: Synjardy

Brivaracetam Tablets 10 mg, 25 mg, 50 mg, 75 mg and 100 mg

Approved: June 9, 2022 - Sunshine Lake Pharma Co., Ltd. Treatment for: Epilepsy Generic for: **Briviact**

Cabazitaxel Intravenous Solution 60 mg/1.5 mL (40 mg/mL) Approved: June 23, 2022 -

Breckenridge Pharmaceutical, Inc. Treatment for: Prostate Cancer Generic for: **Jevtana**

Abiraterone Acetate Tablets 125 mg

Approved: June 24, 2022 - Teva Pharmaceuticals USA, Inc. Treatment for: Prostate Cancer Generic for: **Yonsa**

Estradiol and Progesterone Capsules 1 mg / 100 mg Approved: May 16, 2022 - Amneal Pharmaceuticals

LLC Treatment for: Vasomotor Symptoms Due to Menopause Generic for: **Bijuva**

Iodixanol Injection 55% and 65.2% Approved: May 19, 2022 - Jiangsu Hengrui Pharmaceuticals Co., Ltd. Treatment for: Radiographic Procedures Generic for: Visipaque 270 and Visipaque 320

Lacosamide Oral Solution 10 mg /mL

Approved: May 19, 2022 - Alkem Laboratories Ltd. Treatment for: Seizures Generic for: **Vimpat Oral Solution**

Pemetrexed Disodium Injection 100 mg (base)/vial and 500 mg (base)/vial

Approved: May 25, 2022 - Accord Healthcare, Inc.; Apotex Corp.; Dr. Reddys Laboratories Inc.; Eugia Pharma Specialities Limited; Fresenius Kabi USA, LLC; Hospira, Inc.; Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Nang Kuang Pharmaceutical Co., Ltd.; Qilu Pharmaceutical Co., Ltd.; Waverley Pharma Inc.; Zydus Pharmaceuticals (USA) Inc. Treatment for: Mesothelioma, Non-Small Cell Lung Cancer

Generic for: Alimta

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution 0.2% / 0.5% (base)

Approved: April 4, 2022 - Sandoz Inc. Treatment for: Glaucoma Generic for: **Combigan**

Lacosamide Injection 200 mg/20 mL (10 mg/mL) Approved: April 7, 2022 - Indoco Remedies Limited Treatment for: Seizures Generic for: Vimpat Injection

Cysteine Hydrochloride Injection 500 mg/10 mL (50 mg/mL) Approved: April 8, 2022 - Eton Pharmaceuticals, Inc.

Approved: April 8, 2022 - Eton Pharmaceuticais, Inc. Treatment for: Total Parenteral Nutrition Generic for: **Elcys**

Regadenoson Intravenous Solution 0.4 mg/5 mL (0.08 mg/mL)

Approved: April 11, 2022 - Accord Healthcare, Inc.; Apotex Inc.; Hong Kong King-Friend Industrial Co. Ltd.; Dr. Reddy's Laboratories Ltd. Treatment for: Myocardial Perfusion Imaging Generic for: **Lexiscan** **Bexarotene Topical Gel 1%** Approved: April 27, 2022 - Amneal Pharmaceuticals LLC Treatment for: Cutaneous T-Cell Lymphoma Generic for: **Targretin Gel**

Methylphenidate Extended Release Transdermal Film 10 mg, 15 mg, 20 mg and 30 mg Approved: March 14, 2022 - Mylan Pharmaceuticals Inc. Treatment for: ADHD Generic for: Daytrana

Budesonide and Formoterol Fumarate Dihydrate Metered Inhalation Aerosol 0.08 mg/0.0045 mg per inhalation and 0.16 mg/0.0045 mg per inhalation

Approved: March 15, 2022 - Mylan Pharmaceuticals Inc. Treatment for: Asthma; COPD Generic for: **Symbicort**

Lacosamide Tablets 50 mg, 100 mg, 150 mg and 200 mg

Approved: March 17, 2022 - Alembic Pharmaceuticals Ltd.; Amneal Pharmaceuticals LLC; Glenmark Pharmaceuticals Inc.; Hetero Labs Limited; Indoco Remedies Limited; MSN Laboratories Private Limited; ScieGen Pharmaceuticals Inc., Sun Pharmaceutical Industries, Inc. Treatment for: Seizures Generic for: **Vimpat**

Ioflupane I-123 Injection for Intravenous Use 185 MBq (5 mCi) in 2.5 mL

Approved: March 30, 2022 - Curium US LLC Treatment for: Computed Tomography Generic for: **DaTscan**

Cyclosporine Ophthalmic Emulsion 0.05%

Approved: February 2, 2022 - Mylan Pharmaceuticals, Inc. Treatment for: Dry Eye Disease Generic for: **Restasis**

Information collected and compiled by

Md. Akbar Hossain ASA University (ASAUB) Shyamoli, Mohammadpur Dhaka-1207, Bangladesh

Maraviroc Tablets 150 mg and 300 mg

Approved: February 7, 2022 - Hetero Labs Limited Treatment for: HIV Infection Generic for: **Selzentry**

Nalmefene Hydrochloride Injection 2 mg base /2 mL

Approved: February 8, 2022 - Purdue Pharma LP Treatment for: Opioid Overdose Generic for: **Revex**

Dapagliflozin Tablets 5 mg and 10 mg

Approved: February 22, 2022 - Zydus Pharmaceuticals USA, Inc. Treatment for: Type 2 Diabetes Generic for: **Farxiga**

Apomorphine Hydrochloride Injection 30 mg/3 mL (10 mg/mL)

Approved: February 23, 2022 - Sage Chemicals, Inc. Treatment for: Parkinson's Disease Generic for: **Apokyn**

Pirfenidone Capsules 267 mg

Approved: January 3, 2022 - Amneal Pharmaceuticals LLC Treatment for: Idiopathic Pulmonary Fibrosis Generic for: **Esbriet**

Sofosbuvir Tablets 400 mg

Approved: January 27, 2022 - Teva Pharmaceuticals USA, Inc. Treatment for: Hepatitis C Generic for: **Sovaldi**

Brimonidine Tartrate Ophthalmic Solution 0.15%

Approved: January 31, 2022 - Apotex Inc. Treatment for: Glaucoma Generic for: Alphagan P

Reference: www.drugs.com